The study investigators identified 24 prospective trials with 2,850 patients. The median patient age ranged between 59 and 77 years. Overall, testosterone recovery, defined at 240 ng/dL, was observed ...

This retrospective analysis included 102 patients with advanced RCC treated with either cabozantinib + nivolumab or lenvatinib + pembrolizumab as first-line therapy at Tokyo Women's Medical University ...

Company confirms Hugo RAS system submission to the U.S. Food and Drug Administration ...

Written by: Eman N. Chaudhri, MD, Department of Urology, University of California, Irvine, @EmanChaudhri on Twitter during the American Urological Association's 2025 Annual Meeting, between April 26 – ...

In Q1, the company submitted a supplemental Biologics License Application (sBLA) for use of ANKTIVA® plus Bacillus Calmette-Guérin (BCG) in BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) ...

Nauseef JT, Sun MP, Thomas C, et al. A phase I/II dose-escalation study of fractionated 225Ac-J591 for progressive metastatic castration-resistant prostate cancer in patients with prior treatment with ...

The American Urological Association's 2025 Annual Meeting, between April 26 – 29, 2025, in Las Vegas, Nevada, was host to the Moderated Poster 13: Prostate Cancer: Staging Session. Dr. Claudia Kesch ...

Dr. Huang concluded this presentation discussing results of a phase II study of tislelizumab as neoadjuvant treatment for cisplatin-ineligible high-risk upper tract urothelial carcinoma with the ...

AUA annual meeting featured a prostate cancer session and a presentation by Dr. Madison Krischak discussing access to prostate cancer clinical trials in the VA and whether veterans with prostate ...

Each patient underwent sequential laser activation in three commonly used modes: fragmentation (low power), dusting (moderate power), and pop-dusting (high power), with temperatures recorded ...

(UroToday.com) The American Urological Association's 2025 Annual Meeting, between April 26 – 29, 2025 in Las Vegas, Nevada, was host to the Society of Urologic Oncology (SUO) Session. Dr. Bernard ...

Dr. Kazuyuki Numakura presented a study of primary resistance to nivolumab + ipilimumab therapy affecting second-line treatment outcomes in metastatic renal cell carcinoma (mRCC) patients. Long-term ...